Drug maker Lupin Ltd is expected to soon launch its generic version of the anti-HIV drug, Combivir, in the United States. The move was likely to lend a significant upside to the Mumbai-based company’s bottom line in the forthcoming quarters, a source said.
Lupin’s drug, a combination of lamividine and zidovudine tablets, is a generic version of Viiv Healthcare’s Combivir that is prescribed in combination with other antiretroviral agents for the treatment of HIV-1 infection. “Lupin is likely to launch generic Combivir in the US as early as this month,” the source said. The 1968-founded company is waiting for the final approval from the US Food and Drug Administration (FDA).
Technology Partners: MimirTech
Links:
[1] http://admin.indiaenvironmentportal.org.in/news/lupin-set-launch-anti-aids-generic-drug-us
[2] http://admin.indiaenvironmentportal.org.in/category/author/sushmi-dey
[3] http://admin.indiaenvironmentportal.org.in/category/newspaper/business-standard-new-delhi
[4] http://admin.indiaenvironmentportal.org.in/category/thesaurus/united-states-america-us
[5] http://admin.indiaenvironmentportal.org.in/category/thesaurus/aids
[6] http://admin.indiaenvironmentportal.org.in/category/thesaurus/drug-industry
[7] http://admin.indiaenvironmentportal.org.in/category/thesaurus/drugs
[8] http://admin.indiaenvironmentportal.org.in/category/thesaurus/food-safety-authority-fda
[9] http://admin.indiaenvironmentportal.org.in/category/thesaurus/health
